《大行報告》高盛:友邦(01299.HK)上季新業務價值增長強於預期 維持「買入」評級
高盛發表報告指,友邦保險(01299.HK)上季新業務價值增長強於預期,受惠毛利率復甦,加上所有地區市場毛利率(較上半年而言)持續擴張。該行表示,內地市場新業務價值利潤率連續改善,加上自2020年以來新增部分省份市場,令新業務價值的貢獻佔比持續增加。該行相信,內地市場利潤率於去年上半年下跌,隨後復甦,這有助解決投資者對友邦在內地增長前景的關鍵疑問。
該行表示,留意到集團去年已重新定價大部分在香港及馬來西亞的醫療費用,並計劃今年進一步提高保費率,這或會有助改善集團稅後營運利潤增長。該行給予其目標價97元,評級「買入」,續列「確信買入」名單內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.